Chronic urticaria
MONDO:0850230An urticaria that is characterized by the presence of urticaria for a period exceeding 6 weeks, assuming symptoms for most days of the week.
20 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Ancient herb mix put to the test against stubborn hives
Disease control CompletedThis phase 2 trial tests whether a modified version of the traditional Chinese herbal formula Xiao-Feng Powder can reduce itching and wheals in people with chronic urticaria (hives lasting more than 6 weeks). About 58 adults will receive either the herbal granules or a placebo tw…
Phase: PHASE2 • Sponsor: Prof. Lin Zhixiu • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New pill could stop hives from scratching or cold
Disease control CompletedThis phase 2a trial tested an oral drug called EVO756 in 30 adults with chronic inducible urticaria, a condition where physical triggers like scratching or cold cause hives. The study aimed to see if the drug is safe and can reduce wheals. Results are not yet available.
Phase: PHASE2 • Sponsor: Evommune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New shot could tame stubborn hives that antihistamines Can't stop
Disease control CompletedThis Phase 2 study tested a drug called barzolvolimab (CDX-0159) in 196 adults with chronic inducible urticaria—hives triggered by cold or scratching—that persist despite antihistamines. Participants received either the drug or a placebo as a shot under the skin. The main goal wa…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New biosimilar aims to tame stubborn hives at lower cost
Disease control CompletedThis completed Phase 3 trial tested whether TEV-45779, a biosimilar of the drug omalizumab (XOLAIR), works as well as the original for people with chronic hives that don't improve with antihistamines. 608 participants received either the biosimilar or XOLAIR. The main goal was to…
Phase: PHASE3 • Sponsor: Teva Pharmaceuticals USA • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New tablet shows promise for chronic hives in small study
Symptom relief CompletedThis study tested a daily tablet called NatureU Histra Disslove in 19 adults with chronic hives. Participants took one tablet before a main meal for 28 days. The study measured how well the tablet controlled hives, reduced symptoms, and improved quality of life. Results showed ch…
Phase: NA • Sponsor: OmniSolutions Laboratory Holdings Limited • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Real-World data reveals omalizumab prescribing patterns for chronic hives in china
Knowledge-focused CompletedThis study examined how the drug omalizumab is prescribed in real-world practice for adults with chronic urticaria (long-term hives) in China. Researchers analyzed electronic health records from over 3,400 patients to see what doses were commonly used. The goal was to understand …
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Real-world study tracks xolair dose bumps for stubborn hives
Knowledge-focused CompletedThis study looked at how often doctors increase the dose or give Xolair more frequently for people with chronic hives. Researchers followed 163 adults for 3 months to see how many needed a stronger treatment plan. The goal was to understand real-world use, not to test a new drug.
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Tiny study probes whether viruses trigger stubborn hives
Knowledge-focused CompletedThis completed study took blood samples from 10 people with chronic spontaneous urticaria (long-lasting hives) to check for viral particles. The goal was to see if hidden viruses might be involved in causing the condition. Because it is a small observational study, it can only su…
Sponsor: HaEmek Medical Center, Israel • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:04 UTC